Tricida, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCDA research report →
Companywww.tricida.com
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
- CEO
- Gerrit Klaerner
- IPO
- 2018
- Employees
- 57
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $5.95M
- P/E
- -0.03
- P/S
- 0.00
- P/B
- 24.78
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -355.98%
- ROIC
- -112.13%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-194,168,000 · 26.67%
- EPS
- $-3.88 · 26.65%
- Op Income
- $-158,964,000
- FCF YoY
- 39.79%
Performance & Tape
- 52W High
- $13.85
- 52W Low
- $0.04
- 50D MA
- $0.17
- 200D MA
- $6.86
- Beta
- 0.00
- Avg Volume
- 12.58M
Get TickerSpark's AI analysis on TCDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 22, 22 | ORBIMED ADVISORS LLC | sell | 1,034,421 |
| Nov 23, 22 | ORBIMED ADVISORS LLC | sell | 5,617,300 |
| Nov 25, 22 | ORBIMED ADVISORS LLC | sell | 3,629,226 |
| Nov 22, 22 | Bonita David P | sell | 1,034,421 |
| Nov 23, 22 | Bonita David P | sell | 5,617,300 |
| Nov 25, 22 | Bonita David P | sell | 3,629,226 |
| Nov 23, 22 | Alpern Robert J | sell | 131,879 |
| Nov 21, 22 | Alpern Robert J | sell | 27,584 |
| Oct 24, 22 | Venrock Healthcare Capital Partners II, L.P. | sell | 2,113,948 |
| Oct 25, 22 | Venrock Healthcare Capital Partners II, L.P. | sell | 1,970,418 |
Our TCDA Coverage
We haven't published any research on TCDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TCDA Report →